Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2020

Open Access 01-04-2020 | Breast Cancer | Clinical trial

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study

Authors: J. M. Simons, L. B. Koppert, E. J. T. Luiten, C. C. van der Pol, S. Samiei, J. H. W. de Wilt, S. Siesling, M. L. Smidt

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Abstract

Purpose

An overall trend is observed towards de-escalation of axillary surgery in patients with breast cancer. The objective of this study was to evaluate this trend in patients treated with neoadjuvant systemic therapy (NST).

Methods

Patients with cT1-4N0-3 breast cancer treated with NST (2006–2016) were selected from the Netherlands Cancer Registry. Patients were classified by clinical node status (cN) and type of axillary surgery. Uni- and multivariable logistic regression analyses were performed to determine the clinicopathological factors associated with performing ALND in cN+ patients.

Results

A total of 12,461 patients treated with NST were identified [5830 cN0 patients (46.8%), 6631 cN+ patients (53.2%)]. In cN0 patients, an overall increase in sentinel lymph node biopsy (SLNB) only (not followed by ALND) was seen from 11% in 2006 to 94% in 2016 (p < 0.001). SLNB performed post-NST increased from 33 to 62% (p < 0.001). In cN+ patients, an overall decrease in ALND was seen from 99% in 2006 to 53% in 2016 (p < 0.001). Age (OR 1.01, CI 1.00–1.02), year of diagnosis (OR 0.47, CI 0.44–0.50), HER2-positive disease (OR 0.62, CI 0.52–0.75), clinical tumor stage (T2 vs. T1 OR 1.32, CI 1.06–1.65, T3 vs. T1 OR 2.04, CI 1.58–2.63, T4 vs. T1 OR 6.37, CI 4.26–9.50), and clinical nodal stage (N3 vs. N1 OR 1.65, CI 1.28–2.12) were correlated with performing ALND in cN+ patients.

Conclusions

ALND decreased substantially over the past decade in patients treated with NST. Assessment of long-term prognosis of patients in whom ALND is omitted after NST is urgently needed.
Literature
1.
Mougalian SS, Soulos PR, Killelea BK et al (2015) Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 121(15):2544–2552CrossRef
2.
Vugts G, Maaskant-Braat AJ, Nieuwenhuijzen GA, Roumen RM, Luiten EJ, Voogd AC (2016) Patterns of care in the administration of neo-adjuvant chemotherapy for breast cancer. A population-based study. Breast J 22(3):316–321CrossRef
3.
Giuliano AE, Ballman K, McCall L et al (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 264(3):413–420CrossRef
4.
Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318(10):918–926CrossRef
5.
Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575CrossRef
6.
Giuliano AE, McCall L, Beitsch P et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 252(3):426–432 (discussion 432-423)PubMedPubMedCentral
7.
Galimberti V, Cole BF, Zurrida S et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305CrossRef
8.
Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRef
9.
Dengel LT, Van Zee KJ, King TA et al (2014) Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol 21(1):22–27CrossRef
10.
Mamtani A, Patil S, Van Zee KJ et al (2016) Age and receptor status do not indicate the need for axillary dissection in patients with sentinel lymph node metastases. Ann Surg Oncol 23(11):3481–3486CrossRef
11.
Poodt IGM, Spronk PER, Vugts G et al (2018) Trends on axillary surgery in nondistant metastatic breast cancer patients treated between 2011 and 2015: a Dutch population-based study in the ACOSOG-Z0011 and AMAROS era. Ann Surg 268(6):1084–1090CrossRef
12.
Tsao MW, Cornacchi SD, Hodgson N et al (2016) A population-based study of the effects of a regional guideline for completion axillary lymph node dissection on axillary surgery in patients with breast cancer. Ann Surg Oncol 23(10):3354–3364CrossRef
13.
van Nijnatten TJ, Schipper RJ, Lobbes MB, Nelemans PJ, Beets-Tan RG, Smidt ML (2015) The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review and meta-analysis. Eur J Surg Oncol 41(10):1278–1287CrossRef
14.
Schouten LJ, Höppener P, van den Brandt PA, Knottnerus JA, Jager JJ (1993) Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22(3):369–376CrossRef
15.
Francissen CM, Dings PJ, van Dalen T, Strobbe LJ, van Laarhoven HW, de Wilt JH (2012) Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literature. Ann Surg Oncol 19(13):4140–4149CrossRef
16.
Galimberti V, Cole BF, Viale G et al (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19(10):1385–1393CrossRef
17.
Bilimoria KY, Bentrem DJ, Hansen NM et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27(18):2946–2953CrossRef
18.
Boughey JC (2014) Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy, by Dengel et al. Ann Surg Oncol 21(1):8–10CrossRef
19.
Yi M, Giordano SH, Meric-Bernstam F et al (2010) Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 17(Suppl 3):343–351CrossRef
20.
Hieken TJ, Boughey JC (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases: commentary on the IBCSG 23–01 Trial. Gland Surg 2(3):128–132PubMedPubMedCentral
21.
Weiss A, Mittendorf EA, DeSnyder SM et al (2018) Expanding implementation of ACOSOG Z0011 in surgeon practice. Clin Breast Cancer 18(4):276–281CrossRef
22.
Hunt KK, Yi M, Mittendorf EA et al (2009) Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 250(4):558–566PubMed
23.
Fontein DB, van de Water W, Mieog JS, Liefers GJ, van de Velde CJ (2013) Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy—recommendations for clinical guidance. Eur J Surg Oncol 39(5):417–424CrossRef
24.
van Diest PJ, de Munck L, Sonke GS et al (2015) Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. Eur J Cancer 51(8):915–921CrossRef
25.
Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072–1078CrossRef
26.
Donker M, Straver ME, Wesseling J et al (2015) Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 261(2):378–382CrossRef
27.
van Nijnatten TJA, Simons JM, Smidt ML et al (2017) A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a Dutch prospective multicenter validation study. Clin Breast Cancer 17(5):399–402CrossRef
28.
Diego EJ, McAuliffe PF, Soran A et al (2016) Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol 23(5):1549–1553CrossRef
29.
Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172CrossRef
30.
Mougalian SS, Hernandez M, Lei X et al (2016) Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol 2(4):508–516CrossRef
31.
Yang TJ, Morrow M, Modi S et al (2015) The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol 22(Suppl 3):S495–501CrossRef
32.
Metadata
Title
De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study
Authors
J. M. Simons
L. B. Koppert
E. J. T. Luiten
C. C. van der Pol
S. Samiei
J. H. W. de Wilt
S. Siesling
M. L. Smidt
Publication date
01-04-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05589-3

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue

Letter to the Editor

HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology

Epidemiology

Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?

Epidemiology

The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer

Clinical trial

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

Preclinical study

Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer

Clinical Trial

The long-term effect of age on cardiovascular disease in patients with breast cancer who received chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits